Cargando…

Relapse patterns and radiation dose exposure in IDH wild-type glioblastoma at first radiographic recurrence following chemoradiation

PURPOSE: To quantify the radiation dose distribution and lesion morphometry (shape) at baseline, prior to chemoradiation, and at the time of radiographic recurrence in patients with glioblastoma (GBM). METHODS: The IMRT dose distribution, location of the center of mass, sphericity, and solidity of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Shidoh, Satoka, Savjani, Ricky R., Cho, Nicholas S., Ullman, Henrik E., Hagiwara, Akifumi, Raymond, Catalina, Lai, Albert, Nghiemphu, Phionah L., Liau, Linda M., Pope, Whitney B., Cloughesy, Timothy F., Kaprealian, Tania B., Salamon, Noriko, Ellingson, Benjamin M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622513/
https://www.ncbi.nlm.nih.gov/pubmed/36053452
http://dx.doi.org/10.1007/s11060-022-04123-3
_version_ 1784821786846691328
author Shidoh, Satoka
Savjani, Ricky R.
Cho, Nicholas S.
Ullman, Henrik E.
Hagiwara, Akifumi
Raymond, Catalina
Lai, Albert
Nghiemphu, Phionah L.
Liau, Linda M.
Pope, Whitney B.
Cloughesy, Timothy F.
Kaprealian, Tania B.
Salamon, Noriko
Ellingson, Benjamin M.
author_facet Shidoh, Satoka
Savjani, Ricky R.
Cho, Nicholas S.
Ullman, Henrik E.
Hagiwara, Akifumi
Raymond, Catalina
Lai, Albert
Nghiemphu, Phionah L.
Liau, Linda M.
Pope, Whitney B.
Cloughesy, Timothy F.
Kaprealian, Tania B.
Salamon, Noriko
Ellingson, Benjamin M.
author_sort Shidoh, Satoka
collection PubMed
description PURPOSE: To quantify the radiation dose distribution and lesion morphometry (shape) at baseline, prior to chemoradiation, and at the time of radiographic recurrence in patients with glioblastoma (GBM). METHODS: The IMRT dose distribution, location of the center of mass, sphericity, and solidity of the contrast enhancing tumor at baseline and the time of tumor recurrence was quantified in 48 IDH wild-type GBM who underwent postoperative IMRT (2 Gy daily for total of 60 Gy) with concomitant and adjuvant temozolomide. RESULTS: Average radiation dose within enhancing tumor at baseline and recurrence was ≥ 60 Gy. Centroid location of the enhancing tumor shifted an average of 11.3 mm at the time of recurrence with respect to pre-IMRT location. A positive correlation was observed between change in centroid location and PFS in MGMT methylated patients (P = 0.0007) and Cox multivariate regression confirmed centroid distance from baseline was associated with PFS when accounting for clinical factors (P = 0.0189). Lesion solidity was higher at recurrence compared to baseline (P = 0.0118). Tumors that progressed > 12 weeks after IMRT were significantly more spherical (P = 0.0094). CONCLUSION: Most GBMs recur local within therapeutic IMRT doses; however, tumors with longer PFS occurred further from the original tumor location and were more solid and/or nodular.
format Online
Article
Text
id pubmed-9622513
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-96225132022-11-02 Relapse patterns and radiation dose exposure in IDH wild-type glioblastoma at first radiographic recurrence following chemoradiation Shidoh, Satoka Savjani, Ricky R. Cho, Nicholas S. Ullman, Henrik E. Hagiwara, Akifumi Raymond, Catalina Lai, Albert Nghiemphu, Phionah L. Liau, Linda M. Pope, Whitney B. Cloughesy, Timothy F. Kaprealian, Tania B. Salamon, Noriko Ellingson, Benjamin M. J Neurooncol Research PURPOSE: To quantify the radiation dose distribution and lesion morphometry (shape) at baseline, prior to chemoradiation, and at the time of radiographic recurrence in patients with glioblastoma (GBM). METHODS: The IMRT dose distribution, location of the center of mass, sphericity, and solidity of the contrast enhancing tumor at baseline and the time of tumor recurrence was quantified in 48 IDH wild-type GBM who underwent postoperative IMRT (2 Gy daily for total of 60 Gy) with concomitant and adjuvant temozolomide. RESULTS: Average radiation dose within enhancing tumor at baseline and recurrence was ≥ 60 Gy. Centroid location of the enhancing tumor shifted an average of 11.3 mm at the time of recurrence with respect to pre-IMRT location. A positive correlation was observed between change in centroid location and PFS in MGMT methylated patients (P = 0.0007) and Cox multivariate regression confirmed centroid distance from baseline was associated with PFS when accounting for clinical factors (P = 0.0189). Lesion solidity was higher at recurrence compared to baseline (P = 0.0118). Tumors that progressed > 12 weeks after IMRT were significantly more spherical (P = 0.0094). CONCLUSION: Most GBMs recur local within therapeutic IMRT doses; however, tumors with longer PFS occurred further from the original tumor location and were more solid and/or nodular. Springer US 2022-09-02 2022 /pmc/articles/PMC9622513/ /pubmed/36053452 http://dx.doi.org/10.1007/s11060-022-04123-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Shidoh, Satoka
Savjani, Ricky R.
Cho, Nicholas S.
Ullman, Henrik E.
Hagiwara, Akifumi
Raymond, Catalina
Lai, Albert
Nghiemphu, Phionah L.
Liau, Linda M.
Pope, Whitney B.
Cloughesy, Timothy F.
Kaprealian, Tania B.
Salamon, Noriko
Ellingson, Benjamin M.
Relapse patterns and radiation dose exposure in IDH wild-type glioblastoma at first radiographic recurrence following chemoradiation
title Relapse patterns and radiation dose exposure in IDH wild-type glioblastoma at first radiographic recurrence following chemoradiation
title_full Relapse patterns and radiation dose exposure in IDH wild-type glioblastoma at first radiographic recurrence following chemoradiation
title_fullStr Relapse patterns and radiation dose exposure in IDH wild-type glioblastoma at first radiographic recurrence following chemoradiation
title_full_unstemmed Relapse patterns and radiation dose exposure in IDH wild-type glioblastoma at first radiographic recurrence following chemoradiation
title_short Relapse patterns and radiation dose exposure in IDH wild-type glioblastoma at first radiographic recurrence following chemoradiation
title_sort relapse patterns and radiation dose exposure in idh wild-type glioblastoma at first radiographic recurrence following chemoradiation
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622513/
https://www.ncbi.nlm.nih.gov/pubmed/36053452
http://dx.doi.org/10.1007/s11060-022-04123-3
work_keys_str_mv AT shidohsatoka relapsepatternsandradiationdoseexposureinidhwildtypeglioblastomaatfirstradiographicrecurrencefollowingchemoradiation
AT savjanirickyr relapsepatternsandradiationdoseexposureinidhwildtypeglioblastomaatfirstradiographicrecurrencefollowingchemoradiation
AT chonicholass relapsepatternsandradiationdoseexposureinidhwildtypeglioblastomaatfirstradiographicrecurrencefollowingchemoradiation
AT ullmanhenrike relapsepatternsandradiationdoseexposureinidhwildtypeglioblastomaatfirstradiographicrecurrencefollowingchemoradiation
AT hagiwaraakifumi relapsepatternsandradiationdoseexposureinidhwildtypeglioblastomaatfirstradiographicrecurrencefollowingchemoradiation
AT raymondcatalina relapsepatternsandradiationdoseexposureinidhwildtypeglioblastomaatfirstradiographicrecurrencefollowingchemoradiation
AT laialbert relapsepatternsandradiationdoseexposureinidhwildtypeglioblastomaatfirstradiographicrecurrencefollowingchemoradiation
AT nghiemphuphionahl relapsepatternsandradiationdoseexposureinidhwildtypeglioblastomaatfirstradiographicrecurrencefollowingchemoradiation
AT liaulindam relapsepatternsandradiationdoseexposureinidhwildtypeglioblastomaatfirstradiographicrecurrencefollowingchemoradiation
AT popewhitneyb relapsepatternsandradiationdoseexposureinidhwildtypeglioblastomaatfirstradiographicrecurrencefollowingchemoradiation
AT cloughesytimothyf relapsepatternsandradiationdoseexposureinidhwildtypeglioblastomaatfirstradiographicrecurrencefollowingchemoradiation
AT kaprealiantaniab relapsepatternsandradiationdoseexposureinidhwildtypeglioblastomaatfirstradiographicrecurrencefollowingchemoradiation
AT salamonnoriko relapsepatternsandradiationdoseexposureinidhwildtypeglioblastomaatfirstradiographicrecurrencefollowingchemoradiation
AT ellingsonbenjaminm relapsepatternsandradiationdoseexposureinidhwildtypeglioblastomaatfirstradiographicrecurrencefollowingchemoradiation